Care quality for rheumatoid arthritis patients in Quebec.


Journal

International journal of rheumatic diseases
ISSN: 1756-185X
Titre abrégé: Int J Rheum Dis
Pays: England
ID NLM: 101474930

Informations de publication

Date de publication:
Jul 2019
Historique:
received: 23 10 2018
revised: 04 02 2019
accepted: 27 03 2019
pubmed: 18 4 2019
medline: 30 1 2020
entrez: 18 4 2019
Statut: ppublish

Résumé

The aims of this study were to: (a) measure the proportion of CARTaGENE rheumatoid arthritis (RA) patients fulfilling pre-specified quality indicators (ie disease-modifying antirheumatic drug [DMARD] use, regular follow up, use of folate supplementation, use of vitamin D and calcium, exercise and smoking status); and (b) examine variation in DMARD use with respect to patient age, sex, education and income. A cohort of RA patients was constructed based on the CARTaGENE survey and health administrative database. CARTaGENE is a large, established, population-based study which recruited 19 995 participants from four metropolitan regions in Quebec. Six quality indicators (QI) were assessed; four pertained to RA management and treatment received (use of DMARD therapy, annual medical visits, use of folate supplementation with methotrexate therapy, and use of calcium and vitamin D in steroid-exposed patients) and two pertained to lifestyle factors (physical activity and smoking cessation). QI were reported in terms of proportion of patients fulfilling them. Bayesian logistic regression analyses were preformed to investigate potential variation with DMARD use. Our cohort included 142 RA patients. The QI that pertain to RA pharmacotherapy and medical management ranged 60-80%. Regarding the QI focusing on lifestyle factors, 55% of patients reported performing moderate physical activity and only 16.6% reported current smoking. Results from the Bayesian logistic regression showed no definite associations between DMARD use and patient characteristics (age, education, income and sex). Our findings suggest a seemingly modest performance of Quebec's health-care system for RA patients, with respect to these QI.

Identifiants

pubmed: 30993889
doi: 10.1111/1756-185X.13580
doi:

Substances chimiques

Antirheumatic Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1233-1238

Informations de copyright

© 2019 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.

Auteurs

Zeinab Slim (Z)

Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada.
Division of Clinical Epidemiology, Research Institute of the McGill University Health Center, Montreal, Quebec, Canada.

Cristiano S Moura (CS)

Division of Clinical Epidemiology, Research Institute of the McGill University Health Center, Montreal, Quebec, Canada.

Sasha Bernatsky (S)

Division of Clinical Epidemiology, Research Institute of the McGill University Health Center, Montreal, Quebec, Canada.
Department of Medicine, McGill University, Montreal, Quebec, Canada.

Elham Rahme (E)

Division of Clinical Epidemiology, Research Institute of the McGill University Health Center, Montreal, Quebec, Canada.
Department of Medicine, McGill University, Montreal, Quebec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH